Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767
dowens@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742
drosen@citizen.org

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108
nflorko@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

Feb. 13, 2013

Public Citizen: FDA Should Require Intra-Aortic Balloon Pumps to Be Tested in People for Safety and Effectiveness

Life-Supporting Medical Device Carries Significant Risks, Should Undergo  Clinical Testing Before Being Sold

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should require intra-aortic balloon pump (IABP) devices to undergo human testing before being approved for use in all conditions, Public Citizen said in a letter today to the agency.

However, the agency is recommending that the device be cleared for its most common uses, including heart attacks, without such tests.

The FDA’s proposal is particularly concerning in light of the known risks of the device. Since 2002, 189 deaths and 1,797 injuries associated with the pump have been reported to the FDA. A total of 3,449 malfunctions of IABP devices also have been reported during that time, with the number of such reports rising sharply over the past five years.

IABP devices provide mechanical assistance to the heart in cases where the heart cannot maintain sufficient blood flow to the rest of the body. They are among a number of devices that were on the market prior to the 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act (FDCA), which granted the FDA the authority to review and regulate medical devices before approval. Such devices are therefore known as “preamendment” devices.

For approval purposes, the FDA classifies all medical devices into three regulatory categories, Class I, II or III. Only Class III devices are typically required to undergo clinical testing in human patients to demonstrate safety and efficacy, while Class I and II devices are exempt from this mandate.

Some preamendment devices, including IABP devices, were considered by FDA’s expert advisory panel in 1976 to be life supporting and risky enough to require Class III approval. However, due to a backlog dating back to the original 1976 amendment, the FDA never finalized the process for requiring premarket approval and clinical trials for these devices. The result is that the devices have effectively been treated as Class II devices and have consequently been sold for years without a requirement that they be tested on people to ensure they are safe and effective.

Rather than finalize the process of requiring premarket approval, the FDA is now proposing to forgo the clinical testing process by offering Class II designation for three of the most common uses of the device: acute coronary syndrome (which includes heart attacks) when accompanied by heart dysfunction, congestive heart failure, and before, during or after any surgical procedure. Less common uses will remain in Class III and require premarket approval with clinical testing.

In 2012, the largest randomized clinical trial of the device to date showed that IABP therapy was ineffective for use in heart attack patients with low blood pressure, refuting decades of historical experience on which the FDA is largely basing its recommendation.

“Life-supporting and risky medical devices, such as IABP devices, always should be tested prior to approval to ensure that they are safe and effective for all of the marketed indications,” said Dr. Sammy Almashat, a researcher with Public Citizen’s Health Research Group. “By permanently removing this requirement for the most common uses of these devices, the FDA is dangerously relying on largely unsubstantiated ‘expert consensus’ of the sort that has recently been overturned by rigorous clinical trials.”

Public Citizen is urging the FDA to maintain IABP devices as Class III medical devices and to require premarket approval for all indications.

Read the letter here.

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.